RIO DE JANEIRO--(BUSINESS WIRE)--Cellpraxis (Brazil), USF Health (USA) and UNIFESP (Brazil) presented and evaluated the clinical results of an innovative therapy for Refractory Angina patients (ReACT) in a scientific meeting and workshop in São Paulo, Brazil.
ReACT, a specific cell formulation product has shown to promote sustained Myocardial Neoangiogenesis in patients with Refractory Angina. Refractory Angina is a no-option medical condition in which the patient experiences severe, irreversible, chest pain.
In December, 2009, the results of the first 8 patients with a follow-up of more than 18 months were published in the leading regenerative medicine journal, Cell Transplantation*. The objective of this meeting in February, 2011 was to re-evaluate these 8 patients as well as another 11 new ones, adding up to 19 individuals treated with ReACT in a follow-up of more than 12 months.
Prof. Leslie Willian Miller, Chair of Cardiovascular Research, at the University of South Florida, was in Brazil between February 12th and 15th, participated in an International Seminar of Cell Therapy in Cardiovascular Diseases giving a lecture on Gene and Cell Therapy for Heart Failure and was there to watch while two patients were injected with ReACT. The ReACT procedures were performed simultaneously.
UNIFESP is the largest Federal University in Brazil, located in São Paulo, with Prof. Enio Buffolo as the head of Cardiovascular Surgery.
Cellpraxis is a bioengineering company, dedicated to stem cell therapy, with expertise in translating research into commercially viable products.